Clinical trial · Observational
Lung cAncer Robotic Comparative Study
Comparing Outcomes for Minimally Invasive Techniques for Anatomic Lung Resection for Cancer - A Prospective, Comparative, Non-randomized, Open Label Post-market Observational Cohort Study Within Europe
NCT06038227CI-TRIAL-00107356LARCSrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 15, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260915-000001
Summary
Brief summary (as posted)
To compare outcomes of minimally invasive surgical techniques for the treatment of early-stage non-small cell lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Robotic Assisted Thoracic Surgery | Procedure | — | UNRESOLVED |
| Video Assisted Thoracic Surgery | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Robotic Assisted Thoracic Surgery
- description
- Participants will undergo robotic assisted thoracic surgery (RATS) for segmentectomy or lobectomy.
- interventionNames
- Procedure: Robotic Assisted Thoracic Surgery
- label
- Video Assisted Thoracic Surgery
- description
- Participants will undergo video assisted thoracic surgery (VATS) for segmentectomy or lobectomy.
- interventionNames
- Procedure: Video Assisted Thoracic Surgery
Primary outcomes (2)
- measure
- Patient reported Quality of Life 1
- timeFrame
- 1 month post surgery
- description
- EQ 5D 5L (European Quality of Life Five Dimension) The EQ-5D-5L is a validated and established generic Patient Reported Outcome (PRO) instrument that uses 6 questions to assess patients' quality of life. It includes a vertical EQ visual analog scale (EQ VAS, 0-100 points) and a descriptive EQ-5D-5L system. An algorithm is used to calculate the scores. For the descriptive section of the scale, an index value of 1 represents the best possible health state, while an index value of \<0 (variable) represents the worst possible health state. The EQ VAS score is rated on a scale of 0-100 points. 0 points correspond to the worst possible health status, while 100 points correspond to the best possible health status.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient diagnosed with clinical stage IA1-2 non-small cell lung cancer at time of procedure * Patient scheduled to undergo minimally invasive surgery for NSCLC with either da Vinci robotic assisted surgery or VATs * Aged ≥ 18 years * Must be willing and able to comply with study requirements * Must indicate their understanding of the study and willingness to participate by signing an appropriate informed consent form Exclusion Criteria: * Patients with clinical stage IA3, II, III, and IV lung cancer * Patient receiving a lobectomy/segmentectomy as an emergency procedure * Patients receiving a lobectomy/segmentectomy for metastatic cancer * Patients scheduled to receive a bilobectomy or sleeve-lobectomy * Mental incapacity to understand or consent to study procedures * Anticipated difficulty for patient to comply with protocol requirements * Unable to comply with the follow up schedule * Pregnant or are planning to become pregnant during the study * Life expectancy \< 12 months
References
Publications (2)
- BACKGROUNDPatel YS, Hanna WC, Fahim C, Shargall Y, Waddell TK, Yasufuku K, Machuca TN, Pipkin M, Baste JM, Xie F, Shiwcharan A, Foster G, Thabane L. RAVAL trial: Protocol of an international, multi-centered, blinded, randomized controlled trial comparing robotic-assisted versus video-assisted lobectomy for early-stage lung cancer. PLoS One. 2022 Feb 2;17(2):e0261767. doi: 10.1371/journal.pone.0261767. eCollection 2022. PMID 35108265
- BACKGROUNDSaji H, Okada M, Tsuboi M, Nakajima R, Suzuki K, Aokage K, Aoki T, Okami J, Yoshino I, Ito H, Okumura N, Yamaguchi M, Ikeda N, Wakabayashi M, Nakamura K, Fukuda H, Nakamura S, Mitsudomi T, Watanabe SI, Asamura H; West Japan Oncology Group and Japan Clinical Oncology Group. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. Lancet. 2022 Apr 23;399(10335):1607-1617. doi: 10.1016/S0140-6736(21)02333-3. PMID 35461558